Simvastatin improves left ventricular function after myocardial infarction in hypercholesterolemic rabbits by anti-inflammatory effects

Cardiovascular Research

Volumn 72, Issue 3, 2006, Pages 438-446

  Bauersachs, Johann ^a   Hiss, Katrin ^c   Fraccarollo, Daniela ^a   Laufs, Ulrich ^b   Ruetten, Hartmut ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Cholesterol; Heart failure; Infarction; Inflammation; Statins

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANOSINE TRIPHOSPHATASE; PLACEBO; RAC1 PROTEIN; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DIET; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; ENZYME ACTIVITY; ENZYME RELEASE; EXPERIMENTAL STUDY; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HEART VENTRICLE FUNCTION; HYPERCHOLESTEROLEMIA; INFLAMMATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RABBIT; SARCOPLASMIC RETICULUM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIET; ECHOCARDIOGRAPHY; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MODELS, ANIMAL; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE TYPE III; RABBITS; RAC1 GTP-BINDING PROTEIN; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SIMVASTATIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33750523014     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2006.08.014     Document Type: Article

References (45)

1. Bolognese L., and Cerisano G. Early predictors of left ventricular remodeling after acute myocardial infarction. Am Heart J 138 (1999) S79-S83
2. Bastiaanse E.M., Atsma D.E., and Kuijpers MM. The effect of sarcolemmal cholesterol content on intracellular calcium ion concentration in cultured cardiomyocytes. Arch Biochem Biophys 313 (1994) 58-63
3. Huang Y., Walker K.E., and Hanley F. Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet. Circulation 109 (2004) 97-102
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
6. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunnighake D.B., et al., Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
7. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sánchez-Pascuala R., Hernández G., Díaz C., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101 (1998) 2711-2719
8. Wagner A.H., Kohler T., Ruckschloss U., Just I., and Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20 (2000) 61-69
9. Maack C., Kartes T., Kilter H., Schafers H.J., Nickenig G., Bohm M., et al. Oxygen free radical release in human failing myocardium is associated with increased activity of Rac1-GTPase and represents a target for statin treatment. Circulation 108 (2003) 1567-1574
10. Dhalla N.S., Temsah R.M., and Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 18 (2000) 655-673
11. Ridker P.M. Connecting the role of C-reactive protein and statins in cardiovascular disease. Clin Cardiol 26 (2003) III39-III44
12. Braunwald E., and Bristow M.R. Congestive heart failure: fifty years of progress. Circulation 102 (2000) IV14-IV23
13. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., and Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 3 (1997) 249-254
14. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 108 (2001) 1429-1437
15. Belch J.J., Bridges A.B., Scott N., and Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J 65 (1991) 245-248
16. Mallat Z., Philip I., Lebret M., Chatel D., Maclouf J., and Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 97 (1998) 1536-1539
17. Bauersachs J., Galuppo P., Fraccarollo D., Christ M., and Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104 (2001) 982-985
18. Hayashidani S., Tsutsui H., Shiomi T., Suematsu M., Kinugawa S., Ide T., et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105 (2002) 868-873
19. Yanni E.A. The laboratory rabbit: an animal model of atherosclerosis research. Lab Anim 38 (2004) 246-256
20. Sbarouni E. The effects of raloxifene and simvastatin on plasma lipids and endothelium. Cardiovasc Drugs Ther 17 (2003) 319-323
21. Wajima T., Makita S., and Oshima K. Effects of HR780, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits and cholesterol-fed rabbits. Pharmacology 70 (2004) 123-129
22. Corti R., Osende J.I., Fallon J.T., Fuster V., Mizsei G., Jneid H., et al. The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. J Am Coll Cardiol 43 (2004) 464-473
23. Patel R., Nagueh S.F., Tsybouleva N., Abdellatif M., Lutucuta S., Kopelen H.A., et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104 (2001) 317-324
24. Pliquett R.U., Cornish K.G., and Zucker I.H. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 95 (2003) 700-704
25. Rungwerth K., Schindler U., Gerl M., Schafer S., Licher T., Busch A.E., et al. Inhibition of Na+-H+ exchange by cariporide reduces inflammation and heart failure in rabbits with myocardial infarction. Br J Pharmacol 142 (2004) 1147-1154
26. Okrainec K., Banerjee D.K., and Eisenberg M.J. Coronary artery disease in the developing world. Am Heart J 148 (2004) 7-15
27. van der Harst P., Voors A.A., van Gilst W.H., Bohm M., and van Veldhuisen D.J. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 71 (2006) 443-454
28. Palmiero P., Maiello M., Passantino A., Antoncecchi E., Deveredicis C., DeFinis A., et al. Puglia, Hypertension Working Group, Brindisi, Italy. Correlation between diastolic impairment and lipid metabolism in mild-to-moderate hypertensive postmenopausal women. Am J Hypertens 15 (2002) 615-620
29. Rauchhaus M., Clark A.L., Doehner W., Davos C., Bolger A., Sharma R., et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 42 (2003) 1933-1940
30. Foody J.M., Shah R., Galusha D., Masoudi F.A., Hayranek E.P., and Krumholz H.M. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113 (2006) 1086-1092
31. Tilton R.G., Cole P.A., Zions J.D., Daugherty A., Larson K.B., Sutera S.P., et al. Increased ischemia-reperfusion injury to the heart associated with short-term, diet-induced hypercholesterolemia in rabbits. Circ Res 60 (1987) 551-559
32. Haghighi K., Gregory K.N., and Kranias E.G. Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy. Biochem Biophys Res Commun 322 (2004) 1214-1222
33. Del Monte F., Williams E., Lebeche D., Schmidt U., Rosenzweig A., Gwathmey J.K., et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation 104 (2001) 1424-1429
34. Alonso-Martinez J.L., Llorente-Diez B., Echegaray-Agara M., Olaz-Preciado F., Urbieta-Echezarreta M., and González-Arencibia C. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 4 (2002) 331-336
35. Ferrari R., Bachetti T., Confortini R., Opasich C., Febo O., Corti A., et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92 (1995) 1479-1486
36. Zhang J., Cheng X., Liao Y.H., Lu B., Yang Y., Li B., et al. Simvastatin regulates myocardial cytokine expression and improves ventricular remodeling in rats after acute myocardial infarction. Cardiovasc Drugs Ther 19 (2005) 13-21
37. Nissen S.E. High-dose statins in acute coronary syndrome. JAMA 292 (2004) 1365-1367
38. Ogita H., and Liao J. Endothelial function and oxidative stress. Endothelium 11 (2004) 123-132
39. Grieve D.J., and Shah A.M. Oxidative stress in heart failure. More than just damage. Eur Heart J 24 (2003) 2161-2163
40. Mital S., Loke K.E., Chen J.M., Mosca R.S., Quaegebeur J.M., Addonizio L.J., et al. Mitochondrial respiratory abnormalities in patients with end-stage congenital heart disease. J Heart Lung Transplant 23 (2004) 72-79
41. Kinugawa S., Tsutsui H., Hayashidani S., Ide T., Suematsu N., Satoh S., et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 87 (2000) 392-398
42. Scherrer-Crosbie M., Ullrich R., Bloch K.D., Nakajima H., Nasseri B., Aretz T., et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 104 (2001) 1286-1291
43. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci 95 (1998) 8880-8885
44. Landmesser U., Engberding N., Bahlmann F.H., Schaefer A., Wiencke A., Heineke A., et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110 (2004) 1933-1939
45. Nahrendorf M., Hu K., Hiller K.H., Galuppo P., Fraccarallo D., Schweizer G., et al. Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study. J Am Coll Cardiol 40 (2002) 1695-1700